BPC-157

BPC-157 is not FDA-approved for any human use and is classified as a research compound. In 2023, the FDA placed it in Category 2, meaning it does not meet current safety criteria for pharmacy compounding. While over 100 preclinical studies have been published, human clinical trials remain extremely limited — only three small studies exist as of 2026.

BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protein found in human gastric juice. The "157" refers to its specific amino acid sequence. It was first isolated by researchers at the University of Zagreb, Croatia in the early 1990s.

BPC-157 is available in both injectable and oral forms. Oral administration has shown efficacy for gastrointestinal conditions in animal studies where local GI tract exposure is the mechanism. For systemic effects like tendon or muscle recovery, subcutaneous injection is more commonly studied. The standard acetate salt has low oral bioavailability in standard form, while the arginate salt form reportedly demonstrates significantly higher absorption.

BPC-157 and TB-500 use different mechanisms for tissue recovery. BPC-157 primarily promotes angiogenesis (new blood vessel formation) through VEGFR2 activation and dual nitric oxide pathways, while TB-500 upregulates actin to promote cell migration. BPC-157 has stronger evidence for gut conditions; TB-500 has more cardiac repair data. They are frequently stacked together for complementary effects.

The legal status of BPC-157 is complex and jurisdiction-dependent. It is not FDA-approved for human use and was placed in FDA Category 2 in 2023. WADA banned it in 2022 for competitive athletes. It remains available as a research compound in many jurisdictions. The DOJ has prosecuted at least one compounding pharmacy for BPC-157-related violations. Legal status continues to evolve.

Based on community reports (not clinical data), timelines vary by condition. Gastrointestinal issues often show noticeable improvement within 2-14 days. Musculoskeletal injuries such as tendons, ligaments, and joints typically require 2-6 weeks for significant results. Chronic injuries that have persisted for months may respond more slowly than acute injuries. These timelines are anecdotal and individual responses vary significantly.

This is an unresolved question in the research. BPC-157 promotes angiogenesis (new blood vessel formation), which is the same process tumors use to establish their blood supply. No published studies have demonstrated that BPC-157 promotes tumor growth, but no studies have ruled it out either. Individuals with active cancer or a recent cancer history are generally advised to avoid BPC-157 until research addresses this question.

Preclinical research and community reports suggest that subcutaneous injection near the injury site may produce faster localized results for musculoskeletal conditions. Abdominal subcutaneous injection distributes the compound systemically. For gastrointestinal issues, oral administration targets the GI tract directly. The choice of injection site has not been directly compared in human clinical trials.

For a standard 5mg vial: add 2mL of bacteriostatic water to yield 2,500 mcg/mL. At this concentration, 10 units on a standard U-100 insulin syringe equals 250 mcg. Slowly inject the water along the vial wall — do not shake. Once reconstituted with bacteriostatic water, store refrigerated at 2-8C and use within 4-6 weeks. With sterile water (no preservative), use within 5-7 days.

The acetate and arginate forms refer to different salt preparations of BPC-157. The acetate form is the standard research version with low oral bioavailability in standard form. The arginate form (sometimes marketed as Pentadeca Arginate or PDA) reportedly has significantly higher oral absorption and better stability. However, peer-reviewed head-to-head bioavailability studies comparing the two forms have not been published.

Long-term human safety data does not exist for BPC-157. The most comprehensive safety study (PMID: 32334036) tested repeated doses in animals for 6 weeks with no adverse effects. The only human data comes from a 2-day IV pilot in 2 people (PMID: 40131143). Most community protocols use 4-8 week cycles with off periods. The absence of long-term data means sustained use carries unknown risk.

Gastrointestinal conditions represent the strongest evidence area for BPC-157. A comprehensive review (PMID: 21548867) documented effects on ulcers, fistulas, and inflammatory bowel lesions in animal models. BPC-157 is the only peptide that reached Phase II human trials for inflammatory bowel conditions. The compound is derived from gastric protective protein, giving it a unique mechanism for GI tissue. Community reports suggest improvement in bloating, digestion, and reflux within 2-14 days.

BPC-157 interacts with both the dopamine and serotonin neurotransmitter systems, which is documented across multiple preclinical studies. This interaction may explain neuroprotective properties observed in animal models. It may also account for the anxiety, mood changes, or anhedonia that a subset of users report in community forums. Individuals taking psychiatric medications should be aware of this potential interaction.

Based on known mechanisms and limited safety data, groups who should avoid BPC-157 include: individuals with active cancer or recent cancer history (angiogenesis concern), pregnant or breastfeeding women (no reproductive safety data), WADA-tested athletes (banned since 2022), individuals under 18 (no pediatric studies), and anyone on anticoagulants without physician guidance (theoretical bleeding concern).

Yes. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited substances list in 2022, classified under S0 (non-approved substances). This means any athlete subject to WADA testing — including Olympic, professional, and many collegiate athletes — cannot use BPC-157. USADA (the US Anti-Doping Agency) has also explicitly flagged BPC-157 as prohibited.

Lyophilized (powder) BPC-157 remains stable for years when stored below -18C (standard freezer). At room temperature, the powder degrades over months. Once reconstituted with bacteriostatic water, store refrigerated at 2-8C and use within 4-6 weeks. If reconstituted with sterile water without preservative, use within 5-7 days refrigerated. Avoid exposure to direct sunlight or repeated freeze-thaw cycles.

The BPC-157 plus TB-500 combination is the most commonly discussed peptide stack in recovery communities. The rationale is mechanistic synergy: BPC-157 promotes angiogenesis to supply injured tissue with blood vessels and nutrients, while TB-500 upregulates actin to mobilize repair cells to the site. No clinical trials have studied this combination, but the distinct mechanisms provide a logical basis. Common reported protocols use both compounds simultaneously during the same cycle.

As of March 2026, human clinical data for BPC-157 is extremely limited. Only three small studies have been published: a 2-person IV safety pilot showing no adverse effects (PMID: 40131143), a small retrospective knee pain study reporting significant relief in most participants, and a 12-patient interstitial cystitis pilot reporting substantial symptom improvement. A Phase I trial (NCT02637284) was registered but results were never published. No completed randomized controlled trials exist in humans.